Hepatology Forum最新文献_第10页

Effects of black cumin seed oil on oxidative stress and expression of membrane-cytoskeleton linker proteins, radixin, and moesin in streptozotocin-induced diabetic rat liver. 黑孜然籽油对链脲佐菌素诱导的糖尿病大鼠肝脏氧化应激及膜-细胞骨架连接蛋白、radixin和moesin表达的影响。

IF 0.8

Hepatology Forum Pub Date : 2022-01-01 DOI: 10.14744/hf.2021.2021.0035

Ugur Seker, Seval Kaya, Sevgi Irtegun Kandemir, Dila Sener, Ozlem Unay Demirel, Yusuf Nergiz

{"title":"Effects of black cumin seed oil on oxidative stress and expression of membrane-cytoskeleton linker proteins, radixin, and moesin in streptozotocin-induced diabetic rat liver.","authors":"Ugur Seker, Seval Kaya, Sevgi Irtegun Kandemir, Dila Sener, Ozlem Unay Demirel, Yusuf Nergiz","doi":"10.14744/hf.2021.2021.0035","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0035","url":null,"abstract":"Background and aim: This study examined the effects of black cumin seed oil treatment on oxidative stress and the expression of radixin and moesin in the liver of experimental diabetic rats.Materials and methods: Eighteen rats were divided into 3 equal groups (control, diabetes, treatment). The control group was not exposed to any experimental treatment. Streptozotocin was administered to the rats in the diabetes and treatment groups. A 2.5 mL/kg dose of black cumin seed oil was administered daily for 56 days to the treatment group. At the conclusion of the experiment, the blood level of malondialdehyde (MDA) and glutathione (GSH) was measured. The expression level and the cellular distribution of radixin and moesin in the liver were analyzed.Results: The plasma MDA (3.05±0.45 nmol/mL) and GSH (78.49±20.45 μmol/L) levels in the diabetes group were significantly different (p<0.01) from the levels observed in the control group (MDA: 1.09±0.31 nmol/mL, GSH: 277.29±17.02 μmol/L) and the treatment group (MDA: 1.40±0.53 nmol/mL, GSH: 132.22±11.81 μmol/L). Immunohistochemistry and western blotting analyses indicated that while the level of radixin was not significantly between the groups (p>0.05) and moesin expression was significantly downregulated (p<0.05) in the experimental group, the treatment was ineffective.Conclusion: The administered dose was sufficient to prevent oxidative stress, but was not sufficient to alleviate the effects of diabetes on moesin expression in hepatic sinusoidal cells.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 1","pages":"21-26"},"PeriodicalIF":0.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/2a/hf-3-21.PMC9138912.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10254666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Changes in the clinical characteristics of chronic hepatitis B patients at the initiation of treatment over a 15-year period. 慢性乙型肝炎患者在开始治疗时临床特征的变化超过15年。

IF 0.8

Hepatology Forum Pub Date : 2022-01-01 DOI: 10.14744/hf.2021.2021.0030

Ozgur Bahadir, Ayca Gokcen Degirmenci Salturk, Muzeyyen Arslan Bahadir

{"title":"Changes in the clinical characteristics of chronic hepatitis B patients at the initiation of treatment over a 15-year period.","authors":"Ozgur Bahadir, Ayca Gokcen Degirmenci Salturk, Muzeyyen Arslan Bahadir","doi":"10.14744/hf.2021.2021.0030","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0030","url":null,"abstract":"Background and aim: This study aimed to evaluate the changes in the clinical characteristics of chronic Hepatitis B (CHB) patients at the initiation of treatment over a 15-years period.Materials and methods: The study included 659 treatment-naive CHB patients who started receiving nucleos(t)ide analogs between January 2006 and December 2020. The patients included in the study were divided into three groups of five years each, according to the start date of treatment.Results: The mean age was 46.2±14.5 years and 445 (67.5%) were male. Two hundred and five (31.1%) patients had cirrhosis. Hepatocellular carcinoma (HCC) developed in forty-one patients (6.2%). Compared to patients in Group 1, Group 2 were younger and had lower decompensated cirrhosis, HCC and ascites, had higher Child A cirrhosis (all p<0.05). Cirrhosis and esophageal varices were higher in patients in Group 3 compared to patients in Group 2 (all p<0.05). Entecavir or tenofovir use increased from 66.5% in Group 1 to 99.2% in Group 3 (p<0.05).Conclusion: The mean age at initiation of treatment for CHB patients increased. The patients had less cirrhosis. In the last 5 years, almost all patients were treated with entecavir or tenofovir.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"3 1","pages":"11-15"},"PeriodicalIF":0.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/b9/hf-3-11.PMC9138909.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10253278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome. 免疫球蛋白轻链淀粉样变表现为Budd-Chiari综合征。

IF 0.8

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0028

Mubin Ozercan, Irem Eser, Saba Kiremitci, Bora Peynircioglu, Selim Karayalcin, Ramazan Idilman

{"title":"Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome.","authors":"Mubin Ozercan, Irem Eser, Saba Kiremitci, Bora Peynircioglu, Selim Karayalcin, Ramazan Idilman","doi":"10.14744/hf.2021.2021.0028","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0028","url":null,"abstract":"1.7 mg/dL (normal range: 0.3–1 mg/dL), and albumin level of 2.7 g/ dL (normal range: 3.5–5.5 g/dL) were noted. The results of serologi-cal studies for viral hepatitis, an autoimmune panel, and a metabolic panel were all normal. Her D-dimer level was high: 5321 ng/mL (nor-mal range: <250 ng/mL). The antithrombin-III and protein C activity level was 43% (normal range: 70–125%) and 51% (normal range: 70–140%), respectively. Abdominal ultrasonography (US) revealed hepatomegaly and a diffuse increase in parenchyma heterogenicity. Doppler US suggested no flow in the right hepatic vein. Magnetic resonance imaging (MRI) also showed hepatomegaly, a heterogenic liver parenchyma, and no contrast filling in the right hepatic vein, consistent with right hepatic vein occlusion. Anticoagulant therapy with low-molecular-weight heparin was initiated. She was followed-up in the outpatient clinic. She presented at the outpatient clinic in September with fatigue, dyspnea, and abdominal distension. Ascites and peripheral edema were present. Her total bilirubin level had increased to 5.5 mg/dL, immunohistochemistry amyloidosis. proteomics, spectrometry","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"120-121"},"PeriodicalIF":0.8,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/01/hf-2-120.PMC9138943.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40560987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of transarterial chemoembolization therapy on survival in patients with non-resectable hepatocellular carcinoma: Single-center study results. 经动脉化疗栓塞治疗对不可切除肝癌患者生存的影响:单中心研究结果。

IF 0.8

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0029

Mehmet Kolu, Osman Dere, Suleyman Sonmez

{"title":"The effect of transarterial chemoembolization therapy on survival in patients with non-resectable hepatocellular carcinoma: Single-center study results.","authors":"Mehmet Kolu, Osman Dere, Suleyman Sonmez","doi":"10.14744/hf.2021.2021.0029","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0029","url":null,"abstract":"Background and aim: This study was designed to investigate the tumor response and effect of drug-eluting transarterial chemoembolization (DEB-TACE) treatment on survival in patients diagnosed with hepatocellular carcinoma (HCC).Materials and methods: The records of 40 patients who underwent DEB-TACE between March 2018 and November 2020 were retrospectively analyzed. Follow-up included abdominal computed tomography and measurement of serum albumin, bilirubin, prothrombin time, and alpha-fetoprotein values. The treatment response was evaluated using the European Association for the Study of the Liver criteria.Results: A total of 70 TACE sessions were performed in the 40 study patients with HCC. The etiology was chronic hepatitis B virus (n=32), secondary biliary cirrhosis (n=2), cryptogenic (n=2), or chronic hepatitis C virus (n=4). Based on the TACE response, complete response was observed in 22 patients, a partial response in 8 patients, and progression in 10 patients. Liver transplantation was performed for 4 patients who had a complete response. The formation of new nodules was observed in 8 patients during the follow-up period. In all, 29 patients survived and 11 died.Conclusion: The findings of this study suggest that DEB-TACE had a positive effect on the survival of patients diagnosed with HCC who could not be treated surgically.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"102-106"},"PeriodicalIF":0.8,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/32/hf-2-102.PMC9138947.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection? 核苷类似物对COVID-19和乙型肝炎病毒合并感染的严重后果有效吗?

IF 0.8

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0027

Gupse Adali, Pinar Gokcen, Fatih Guzelbulut, Ayca Gokcen Degirmenci Salturk, Nihat Bugra Agaoglu, Busra Unal, Levent Doganay, Kamil Ozdil

{"title":"Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?","authors":"Gupse Adali, Pinar Gokcen, Fatih Guzelbulut, Ayca Gokcen Degirmenci Salturk, Nihat Bugra Agaoglu, Busra Unal, Levent Doganay, Kamil Ozdil","doi":"10.14744/hf.2021.2021.0027","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0027","url":null,"abstract":"Background and aim: The impact of chronic hepatitis B virus (HBV) infection and nucleos(t)ide analogue (NUC) treatment on disease severity and clinical outcomes in patients with coronavirus 2019 (COVID-19) is unknown. The objective of this study was to determine whether HBV infection and the use of NUCs impacts mortality in patients with COVID-19.Materials and methods: A total of 231 adult patients (77 with COVID-19 and HBV coinfection) with a laboratory-confirmed diagnosis of COVID-19 were enrolled in this retrospective study. Univariate and binary logistic regression analysis were performed to evaluate the risk factors for mortality from COVID-19.Results: Patients with COVID-19 and HBV coinfection had a similar rate of mortality to those without HBV coinfection (7.8% vs 9.7%; p=0.627). Cardiovascular disease (odds ratio [OR]: 8.22, 95% confidence interval [CI]: 1.52-44.2; p=0.014) and a high basal aspartate transaminase level (OR: 7.94, 95% CI: 1.81-34.8; p=0.006) were independent predictors of mortality due to COVID-19. In the COVID-19 and HBV coinfection group, the patients who died had a significantly higher median level of HBV DNA than patients who survived (378 IU/mL vs 0 IU/mL; p=0.048). Thirty (39%) patients with HBV coinfection received NUC treatment, and none of these patients died.Conclusion: HBV infection was not associated with mortality in patients with COVID-19, and it seems that NUC treatment for HBV infection might have an antiviral effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"91-96"},"PeriodicalIF":0.8,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/a8/hf-2-91.PMC9138945.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor. 抗 HBc、HBsAg 阴性供体肝移植后新发乙型肝炎表面抗原 (HBsAg) 阳性、核心抗体 (anti-HBc) 阴性的乙型肝炎病毒感染。

IF 1.2

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0019

Harjot K Bedi, Roberto Trasolini, Christopher F Lowe, Trana Hussaini, Mark Bigham, Gordon Ritchie, Eric M Yoshida

{"title":"De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor.","authors":"Harjot K Bedi, Roberto Trasolini, Christopher F Lowe, Trana Hussaini, Mark Bigham, Gordon Ritchie, Eric M Yoshida","doi":"10.14744/hf.2021.2021.0019","DOIUrl":"10.14744/hf.2021.2021.0019","url":null,"abstract":"Liver transplant donors and recipients are routinely screened for hepatitis B virus (HBV) infection by measuring the levels of hepatitis B surface antigen (HBsAg) and hepatitis B core (anti-HBc) antibodies. Organs are accepted from donors who are HB-negative, and increased monitoring is required for organs from donors considered at increased risk. Transplant recipients are vaccinated if there is no sign of previous infection or immunity and monitored for reactivation in case of previous HBV infection. In cases where both the donor and the recipient are HBV-negative, no antiviral prophylaxis is used post transplant. This report describes a case of an HBV-immunized, anti-HBc-negative patient who underwent an orthotopic liver transplant from an anti-HBc-negative donor. The patient did not receive post-transplant antiviral prophylaxis due to mutual anti-HBc-seronegative status. However, the recipient developed HBV infection with isolated HBsAg and persistently negative anti-HBc. Mutations in the core/pre-core regions of the HBV gene were not implicated for unique serology in this case. Immunosuppression post liver transplant is the likely etiology for isolated HBsAg seroconversion despite significantly elevated HBV DNA. Our experience suggests that HBV DNA screening of liver transplant donors and recipients, in addition to HBV DNA monitoring of recipients, may reduce the risk of transplant-associated HBV.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"117-119"},"PeriodicalIF":1.2,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/b1/hf-2-117.PMC9138942.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40569663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of SARS-COV-2-related hepatic injury. sars - cov -2相关肝损伤综述

IF 1.2

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0020

Abdullah Tarik Aslan, Hatice Yasemin Balaban

{"title":"An overview of SARS-COV-2-related hepatic injury.","authors":"Abdullah Tarik Aslan, Hatice Yasemin Balaban","doi":"10.14744/hf.2021.2021.0020","DOIUrl":"10.14744/hf.2021.2021.0020","url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), is highly contagious and has a variety of clinical manifestations, including liver injury. There have been a few reports indicating acute-on chronic liver failure among COVID-19 patients, however, patients with COVID-19-related liver injury are generally asymptomatic and present with a mild to moderate elevation in serum hepatic enzymes. Severe COVID-19 patients have high rates of liver injury with poorer outcomes. The pattern of abnormalities in liver biochemical indicators may be hepatocellular, cholestatic, or mixed. Although the pathogenesis of hepatic injury is not yet completely understood, causes of liver damage include systemic inflammatory response syndrome, ischemia-reperfusion injury, side effects of medications, and underlying chronic liver disease. While viral RNA has been detected in hepatocytes, it remains unknown if the coronavirus has the capacity to cause cytopathic effects in hepatic tissue. Additionally, it is important to remember that the current upheaval to daily life and access to healthcare caused by the COVID-19 pandemic has had a significant and negative effect on other patients with chronic liver disease. The objective of this review was to summarize the current literature on COVID-19-related hepatic injury with an examination of clinical features, potential pathogenesis, and histopathological findings of this entity.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"122-127"},"PeriodicalIF":1.2,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/3e/hf-2-122.PMC9138946.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brucellosis as a rare cause of granulomatous hepatitis with hepatic and bone marrow granulomas: A case report. 布鲁氏菌病是肉芽肿性肝炎合并肝和骨髓肉芽肿的罕见病因:1例报告。

IF 0.8

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0038

Kendal Yalcin, Elif Tugba Tuncel, Feyzullah Ucmak, Remzi Bestas

{"title":"Brucellosis as a rare cause of granulomatous hepatitis with hepatic and bone marrow granulomas: A case report.","authors":"Kendal Yalcin, Elif Tugba Tuncel, Feyzullah Ucmak, Remzi Bestas","doi":"10.14744/hf.2021.2021.0038","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0038","url":null,"abstract":"Brucellosis is a zoonotic infection that may involve the liver in a variety of ways, however, data on the histopathology of liver effects in brucellosis are limited. Brucellosis is generally characterized by a high fever, joint or back pain, and hepatosplenomegaly. This report illustrates a case of granulomatous hepatitis with granulomas in the liver and bone marrow in a patient who presented with non-specific symptoms, hepatomegaly, splenomegaly, digital clubbing, and laboratory signs of intrahepatic cholestasis. Granulomas were detected in the bone marrow and hepatic specimens. The diagnosis of brucellosis was based on the isolation of Brucella mellitensis in a blood culture and serum agglutination titers of 1:640. Treatment for brucellosis led to improved laboratory and clinical findings. Brucellosis should be considered in regions where it is endemic in cases of an elevated transaminase level and related clinical findings. Brucellosis should also be considered in the differential diagnosis of intrahepatic cholestasis and/or granulomas in hepatic and bone marrow biopsies. This case report provides valuable histopathological features and detailed information of liver involvement in a case of brucellosis.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"137-140"},"PeriodicalIF":0.8,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e8/35/hf-2-137.PMC9138939.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease. 在患有代谢相关性脂肪肝的肥胖患者中开展基于饮食的适度卡路里限制的可持续性。

IF 1.2

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0014

Hakan Guveli, Tugce Ozlu, Busra Ersoy Tasar, Emre Batuhan Kenger, Eda Kaya

{"title":"Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease.","authors":"Hakan Guveli, Tugce Ozlu, Busra Ersoy Tasar, Emre Batuhan Kenger, Eda Kaya","doi":"10.14744/hf.2021.2021.0014","DOIUrl":"10.14744/hf.2021.2021.0014","url":null,"abstract":"Background and aim: The long-term sustainability of weight loss continues to be a subject of investigation. This study was designed to examine the effects of weight loss and the long-term sustainability of lifestyle modifications among obese patients with metabolic-associated fatty liver disease (MAFLD).Materials and methods: A total of 40 patients who were prescribed a hypocaloric diet (~500 calories reduction for each patient), and who were followed up for 12 weeks in 4 face-to-face interviews were enrolled in the study. The patients were contacted at the 36th month, and their current weight was recorded.Results: The mean weight at baseline of 87±13 kg decreased to 79±11 kg after 12 weeks of intervention (p<0.001). The mean weight at the 36th month did not significantly differ from that measured at the baseline (p=0.563). The mean controlled attenuation parameter decreased from 320±13 dB/m to 273±37 dB/m (p<0.001), while the median liver stiffness measurement decreased from 8.7 kPa (3.6-45.7 kPa) to 5.7 kPa (2.2-29.9 kPa) (p<0.001).Conclusion: Strict follow-up through nutritional consultation can help achieve weight loss in obese patients with MAFLD. However, for long-term results, the collaboration of nutritionists and gastroenterologists is essential to prevent weight regain.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"97-101"},"PeriodicalIF":1.2,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/df/hf-2-97.PMC9138938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between polyphenols and miRNAs: A novel therapeutic strategy for metabolic associated fatty liver disease. 多酚和mirna之间的关系:代谢相关脂肪肝疾病的新治疗策略

IF 0.8

Hepatology Forum Pub Date : 2021-09-15 eCollection Date: 2021-09-01 DOI: 10.14744/hf.2021.2021.0037

Hatice Merve Bayram, Fatih Eren, Fatma Esra Gunes

{"title":"The relationship between polyphenols and miRNAs: A novel therapeutic strategy for metabolic associated fatty liver disease.","authors":"Hatice Merve Bayram, Fatih Eren, Fatma Esra Gunes","doi":"10.14744/hf.2021.2021.0037","DOIUrl":"https://doi.org/10.14744/hf.2021.2021.0037","url":null,"abstract":"Metabolic-associated fatty liver disease (MAFLD) is a public health problem that is increasingly recognized, currently affecting up to a quarter of the world's adult population. Although a biopsy is the current gold standard to diagnose MAFLD, there are potentially serious complications, making it inadequate. Thus far, noninvasive methods have not been able to determine the stage and the subtype of MAFLD. The development and prognosis of MAFLD are modulated by epigenetic factors, including microRNAs (miRNAs), which may be potential biomarkers for MAFLD. Polyphenols, found in many fruits and vegetables, may be useful, as they alter gene expression with epigenetic factors, such as miRNAs. This review presents an overview of the relationship between polyphenols and miRNAs in MAFLD. The literature suggests that miRNAs could be used as a diagnostic method for MAFLD, especially miRNA-122 and miRNA-34a. However, though it has been demonstrated that polyphenols may contribute to improving MAFLD, to our knowledge, no study to date has shown the relationship between polyphenols and miRNAs in MAFLD. The exact mechanisms of polyphenols on miRNAs in MAFLD remain unclear. Future studies may provide hope for diet therapy for MAFLD patients as well as the development of polyphenol-related foods or drugs that target miRNAs to treat MAFLD.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"2 3","pages":"128-136"},"PeriodicalIF":0.8,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/43/hf-2-128.PMC9138948.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4